TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01493856
Drug: DWJ1276
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet, Rosuvastatin 20mg and olmesartan medoxomil 40mg
Study: NCT00835497
Drug: 5 mg/500 mg METAGLIP™ Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x 5 mg/500 mg, single-dose fasting
Study: NCT04065919
Drug: 0.25% Bupivacaine with epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25% Bupivacaine with epinephrine at 1cc/kg total dose infiltrated into 5th intercostal space
Study: NCT03000036
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients had prescribed endovenous doxorubicin as part of their chemotherapy regimen (mean cumulative dose 102,66 mg/m2, administered in 4 doses with 21 days interval).
Study: NCT00537420
Drug: Nasal Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal placebo, three times a day, 30 minutes before a meal for 24 weeks.
Study: NCT00537420
Drug: Placebo Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules will be taken once daily with or without food.
Study: NCT00259558
Drug: retarded release phosphatidylcholine
Normalized name: phosphatidylcholine, soybean
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02262754
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for PF-06372865 and placebo for naproxen daily
Study: NCT02262754
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500 mg BID for 4 weeks
Study: NCT02281136
Drug: Aminolevulinic Acid (ALA)
DrugBank: Aminolevulinic acid (DB00855)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light
Study: NCT01825408
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects with CRSwNP who are not allergic to doxycycline will receive Doxycycline 100mg BID for either 3 or 6 weeks duration.
Study: NCT01825408
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects with CRS without Nasal Polyposis (CRSwNP)who are not allergic to azithromycin will be given Azithromycin 250mg daily for either 3 or 6 weeks duration.
Study: NCT00317408
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00317408
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00317408
Drug: prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00012051
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002961
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Arms A and B Day 2 and 3: Cyclophosphamide 60 mg/kg intravenously; Administer 20 mg/ml concentration over 2 hours.
Study: NCT00176293
Drug: doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin 50mg/m\^2 I.V. on day 5
Study: NCT03212625
Drug: Urea Cream 20%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib 400mg (twice daily), Spread urea cream (urea 20%)
Study: NCT03212625
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib 400mg (twice daily), Spread placebo cream (urea 0%)
Study: NCT00482079
Drug: Comparator: placebo (unspecified) / Duration of Treatment: 21 Weeks
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00002961
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: methotrexate 15 mg/m2 IV on day +1 (do not give until 24 hours after marrow infusion), and 10mg/mg2 IV on days +3 and +6.~Methotrexate may be held after two doses for bilirubin .2 mg/dL. If serum creatinine is \>2x baseline, methotrexate will be omitted. If the presence of ascites or pleural effusion, methotrexate will be omitted.
Study: NCT04521491
Drug: FOLFOX4(infusional fluorouracil [FU], leucovorin [LV], and oxaliplatin [OXA]).
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOX4 (OXA 85 mg/m2 intravenously \[IV\] on day 1; LV 200 mg/m2 IV from hour 0 to 2 on days 1 and 2; and FU 400 mg/m2 IV bolus at hour 2, then 600 mg/m2 over 22 hours on days 1 and 2, once every 2 weeks.All patients in the treatment group will receive FOLFOX4 at most 12 times beginning from the 4th week after liver resection.
Study: NCT00799617
Drug: AndroGel® (testosterone gel)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone levels will be measured at regular intervals in order to achieve a testosterone level in the desired range.
Study: NCT00799617
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone levels will be measured at regular intervals.
Study: NCT03385239
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile Normal Saline (0.9% NaCl).
Study: NCT02667938
Drug: HCP1303 capsule 5/0.2mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02086422
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02667938
Drug: HCP1303 capsule 5/0.4mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02945644
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: take at bedtime for 14 days
Study: NCT03281304
Drug: CP-690,500 5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: CP-690,550 5 mg tablet BID
Study: NCT03281304
Drug: CP-690,550 10 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: CP-690,550 10 mg tablet BID
Study: NCT02667938
Drug: HGP1201
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02648672
Drug: BPN14770
Approvals — FDA: no, EMA: no, PMDA: no
Description: BPN14770 is an investigational new drug being developed for the treatment of Alzheimer's disease and other cognitive disorders. BPN14770 is a small molecule, subtype selective, negative allosteric modulator of phosphodiesterase 4D.
Study: NCT02648672
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03878303
Drug: AC0058TA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg capsules
Study: NCT03878303
Drug: Placebo AC0058TA
Approvals — FDA: no, EMA: no, PMDA: no
Description: equivalent dose of investigational product
Study: NCT02789592
Drug: Melatonin PR
Approvals — FDA: no, EMA: no, PMDA: no
Description: For experimental treatment of RBD
Study: NCT01478165
Drug: Total intravenous anesthesia
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anesthesia plus normal saline 1.5 ml immediately before induction of anesthesia
Study: NCT02667938
Drug: HCP1303 capsule 5/0.2mg placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02789592
Drug: Melatonin PR placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pill manufactured to mask melatonin PR 2mg tablet
Study: NCT02667938
Drug: HCP1303 capsule 5/0.4mg placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02188186
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventioanl treament with dose escalation
Study: NCT02667938
Drug: HGP1201 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04495088
Drug: mFOLFOX (neoadjuvant)
Approvals — FDA: no, EMA: no, PMDA: no
Description: neoadjuvant application Folinic acid: 400 mg/m2, 2h i.v., on day 1 Oxaliplatin: 85 mg/m2, 2-6h i.v., on day 1 5-FU: 2400 mg/m2, 46-48h i.v., on day 1. Cycles are repeated on day 15. A total of 6 cycles are administered.
Study: NCT04495088
Drug: XELOX (neoadjuvant)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: neoadjuvant application Capecitabine: 1,000 mg/m2 bid, po, on days 1-14 Oxaliplatin: 130 mg/m2, 2-6h i.v. day 1 Cycles are repeated on day 22. A total of 4 cycles are administered.
Study: NCT04495088
Drug: mFOLFOX (adjuvant)
Approvals — FDA: no, EMA: no, PMDA: no
Description: adjuvant application Folinic acid: 400 mg/m2, 2h i.v., on day 1 Oxaliplatin: 85 mg/m2, 2-6h i.v., on day 1 5-FU: 2400 mg/m2, 46-48h i.v., on day 1. Cycles are repeated on day 15. A total of 6 cycles are administered.
Study: NCT04495088
Drug: XELOX (adjuvant)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: adjuvant application Capecitabine: 1,000 mg/m2 bid, po, on days 1-14 Oxaliplatin: 130 mg/m2, 2-6h i.v. day 1 Cycles are repeated on day 22. A total of 4 cycles are administered.
Study: NCT04495088
Drug: Capecitabine (adjuvant)
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: adjuvant application Capecitabine: 1,250 mg/m2 bid, po, on days 1-14 Cycles are repeated on day 22. A total of 8 cycles are administered.
Study: NCT04495088
Drug: infusional 5-FU/FA AIO regimen (adjuvant)
Approvals — FDA: no, EMA: no, PMDA: no
Description: adjuvant application Folinic acid 2h i.v. 500 mg/m² 5-FU 2,600mg/m² (24h infusion) Days 1, 8, 15, 22, 29, 36; cycle is repeated day 57 (representing one cycle); a total of 3 cycles should be administered.
Study: NCT04495088
Drug: infusional 5-FU/FA de Gramont (adjuvant)
Approvals — FDA: no, EMA: no, PMDA: no
Description: adjuvant application Folinic acid 2h i.v. 200 mg/m² days 1 and 2 5-FU 400mg/m² bolus followed by 600mg/m² 22h infusion days 1 and 2 The cycle is repeated day 15; a total of 12 cycles should be administered.
Study: NCT03657472
Drug: CJ-30061
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Test: CJ-30061(Fixed-dose combination drug containing Amlodipine 5mg/Valsartan 160mg/Atorvastatin 20mg)
Study: NCT03657472
Drug: Exforge® 5/160mg & Lipitor® 20mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference: Co-administration of Exforge® tab 5/160mg and Lipitor® tab 20mg
Study: NCT00970606
Drug: Rosuvastatin (crestor)
Normalized name: rosuvastatin Oral Tablet [Crestor]
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 20 mg tablets once daily x max 28 days or for an additional 3 days following ICU discharge
Study: NCT00970606
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet identical to active therapy. 1 tablet per day
Study: NCT04426695
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo IV Single Dose
Study: NCT04562155
Drug: BAY1817080
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study drug BAY1817080 will be administered orally as tablet.
Study: NCT04562155
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo for BAY1817080 will be administered orally as tablet.
Study: NCT03787992
Drug: Placebo AST2818 80mg//40 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: The initial dose of Placebo AST2818 80 mg once daily can be reduced to Placebo AST2818 40 mg once daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
Study: NCT00694980
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous and subcutaneous escalating doses
Study: NCT00816868
Drug: erlotinib in combination with capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Erlotinib 150 mg Q.D. orally for 21 days plus Capecitabine 1000 mg/m2 twice daily for 2 weeks followed by 1 week break every 21 days Until PD, unacceptable toxicity or death.
Study: NCT00955266
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline, 50cc delivered over 5 minutes
Study: NCT04317248
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous drip，250mg/m\^2 per time，two days before each times of MSDCV therapy，total 6 times, in order to improve the immunosuppressive microenvironment of tumor，reduce CD4+CD25+FOXP3+regulatory T cells (Tregs）
Study: NCT03317119
Drug: Trifluridine and Tipiracil Hydrochloride
Normalized name: tipiracil / trifluridine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT04473651
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo - capsules, orally (Part A only)
Study: NCT01640730
Drug: Kanglaite Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30gm IV infusion 5 days a week for 3 weeks every 28 days
Study: NCT03407872
Drug: Placebo DPI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive different cycle of treatment consisting of 4 dosing sequences administered within 2 weeks. Participants in this part will be randomized to receive Esketamine DPI or placebo in 3:1 ratio.~In each cohort, number of placebo inhalations within a dosing sequence will correspond to number of Esketamine DPI inhalations.
Study: NCT02174653
Drug: EPs® 7630
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg EPs® 7630 film-coated tablets during 4 months Orally intake three times a day (in the morning, midday and evening)
Study: NCT02174653
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control: Placebo film coated tablets during 4 months Orally intake three times a day (in the morning, midday and evening)
Study: NCT01820052
Drug: Oral Iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: 230 mg of elemental oral iron tablets will be administered daily for 3 months
Study: NCT01820052
Drug: Oral Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets matching oral iron will be administered daily for 3 months
Study: NCT01813318
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects receiving placebo will be dosed similarly to the acamprosate group.
Study: NCT03641352
Drug: CKD-501 0.5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: CKD-501 0.5mg, orally, 1 tablet once a dqy for 24weeks or 52weeks (if extension study) with D150 and D759
Study: NCT03641352
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, orally, 1 tablet once a dqy for 24weeks or 52weeks (if extension study) with D150 and D759. CKD-501 placebo will be changed to CKD-501 from extension study to EOS(end of study).
Study: NCT00734071
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vortioxetine placebo-matching capsules
Study: NCT03143751
Drug: NaCl20% (Continuous hyperosmolar therapy)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early intravenous administration (\<24 hours after traumatic brain injury) of NaCl20% for a minimal duration of 48 hours (continued for as long as is necessary to prevent intracranial hypertension)~1-hour bolus (15 g if Na+ \< 145 mmol/L; 7.5 g if 145 \< Na+ \< 150 mmol/L; or no bolus) followed by 1 g/hour as long as Na+\< 150 mmol/L, reduced to 0.5 g/L if 150 \< Na+ \< 155 mmol/L, Discontinuation when 155 mmol/L\<Na+
Study: NCT00505947
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo 5 mg/Kg body weight by intravenous infusion
Study: NCT00053807
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02045693
Drug: DCV 3DAA FDC
Normalized name: DYE FDC BLUE #1
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00649831
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin 250 mg tablet; take 2 tablets by mouth on the first day, then 1 tablet by mouth from Days 2 to 5
Study: NCT01650740
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: small placebo capsule (30 mg duloxetine equivalent) x 1 week followed by 60 mg equivalent capsule daily
Study: NCT01679002
Drug: BIA 2-093
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01679002
Drug: Oxcarbazepine
Normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02442258
Drug: ABT-493
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of ABT-493 will be given orally in combination with ABT-530.
Study: NCT02442258
Drug: ABT-530
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of ABT-530 will be given orally in combination with ABT-493.
Study: NCT01350089
Drug: Comparator 1 (with alcohol; without caffeine and energy drink)
Normalized name: Acetaminophen and Caffeine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixture of 46.5 g ethanol (inform of vodka (37.5%)), (carbonated) water 250 mL, artificial fruit juice (21 g/L prepared with (carbonated) water). The final volume of the mixture 500 mL.
Study: NCT01350089
Drug: Comparator 3 (with alcohol and energy drink)
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mixture of 46.5 g ethanol (inform of vodka (37.5%)), Red Bull® Energy Drink (250 mL, without flavour mixture to optimize blinding), artificial fruit juice (21 g/L prepared with (carbonated) water).The final volume of the mixture is 500 mL.
Study: NCT02552303
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for Nuvigil (armodafinil)
Study: NCT04534842
Drug: SYNB1618
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15-day dose-ramp regimen (4 dose levels) of orally administered SYNB1618
Study: NCT04524403
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for once-daily oral dosing
Study: NCT00820404
Drug: BLI-489
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00820404
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03731260
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet
Study: NCT01007461
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% Sodium Chloride (NaCl) will be administered in the same manner as the experimental drug.
Study: NCT04214639
Drug: IDP-126 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDP-126 Gel applied topically to the face once daily for 12 weeks.
Study: NCT04214639
Drug: IDP-126 Vehicle Gel
Normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDP-126 Vehicle Gel applied topically to the face once daily for 12 weeks.
Study: NCT01940536
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00086099
Drug: Idarubincin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idarubincin (12mg/m2) and ara-C(N-18)
Study: NCT01433263
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01504334
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo（without active ingredient） tablets will be taken 3 times a day during the whole study process. For the first week, 1 tablet will be taken each time. For the second week, 2 tablets will be taken each time. From the third week to the 48th week, 3 tablets will be taken each time. Base drug Acetyl Cysteine Tablets（600mg）will be taken once a day, 1 tablet each time from the first to the 48th week for both groups.
Study: NCT01523483
Drug: placebo vaginal capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two placebo capsules placed (soy lecithin and sunflower oil) into the posterior vaginal fornix once daily for up to 36+6 weeks of gestation.
Study: NCT00581867
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01929668
Drug: Ascorbic Acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00547950
Drug: :Deng Zhan Sheng Mai Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsule，0.18g，2＃，po，Bid\*1year.
Study: NCT02266875
Drug: hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02266875
Drug: standard saline
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01107470
Drug: hFSH（Fostimon）
Approvals — FDA: no, EMA: no, PMDA: no
Description: After down-regulation (short protocol), all patients will be stimulated with hFSH (human-derived FSH).
Study: NCT01107470
Drug: hFSH（Fostimon）
Approvals — FDA: no, EMA: no, PMDA: no
Description: After down-regulation (long protocol), all patients will be stimulated with hFSH (human-derived FSH).
Study: NCT01633944
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo Buccal Film twice daily
Study: NCT02694224
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: dose dense Cyclophosphamide (600 mg/m2) together with Epirubicin each 2 weeks x 4 doses with GMCSF after Paclitaxel
Study: NCT01872572
Drug: Subcutaneous RB006 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous RB006 0.5 mg/kg
Study: NCT01872572
Drug: Subcutaneous RB006 1.0 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous RB006 1.0 mg/kg
Study: NCT01872572
Drug: Subcutaneous RB006 3.0 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous RB006 3.0 mg/kg
Study: NCT01872572
Drug: Subcutaneous RB006 2.0 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Arm 1: 4 subjects received an IV bolus injection of 1 mg/kg RB007 at 72 hours post-RB006 administration~* Arm 2: 4 subjects received an IV bolus injection of 1 mg/kg RB007 at 24, 72, and 120 hours post-RB006 administration.
Study: NCT01872572
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00909636
Drug: ABT-333
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: See arm description for more information
Study: NCT00909636
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: See arm description for more information
Study: NCT02488629
Drug: SCB01A
Approvals — FDA: no, EMA: no, PMDA: no
Description: This study is a single arm, open-label, Phase II trial
Study: NCT05236309
Drug: Jing-Guan-Fang(JGF) : Chinese herbal decoction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use 100ml JGF decoction per day as a preventive measure for patients with COVID-19.
Study: NCT01464320
Drug: ABT-614
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active
Study: NCT01464320
Drug: Placebo Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03912233
Drug: TEZ/IVA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination tablets for oral administration.
Study: NCT03912233
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebos matched to VX-121, TEZ, and VX-561 for oral administration.
Study: NCT03806426
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500mg capsule, two 500mg capsules to be taken twice daily for 24 months